By admin 
The Biological Challenge of Ewing Sarcoma
Ewing sarcoma is the second most common primary bone malignancy in children and young adults, characterized by a high degree of aggressiveness and a propensity for early metastasis, particularly to the lungs and other bones. The disease is primarily driven by a chromosomal translocation, most commonly involving the EWS gene on chromosome 22 and the FLI1 gene on chromosome 11. While localized cases have seen improvements in outcomes through a combination of intensive chemotherapy, radiation, and surgery, the metastatic form of the disease frequently develops resistance to conventional cytotoxic agents.
The primary hurdle in treating metastatic ES lies in the "cold" nature of its tumor microenvironment. Unlike some adult cancers that are easily recognized by the immune system, Ewing sarcoma often lacks the high mutational burden that triggers a natural immune response. Furthermore, the tumor microenvironment in ES is notoriously immunosuppressive, effectively creating a shield that prevents the body’s T-cells from identifying and destroying malignant cells. Dr. Lee’s research specifically targets this defensive mechanism, seeking to turn the patient’s own immune system into a more potent weapon.
Harnessing CAR T-Cell Therapy and Interleukin-18
Dr. Lee’s preclinical work centers on the advancement of Chimeric Antigen Receptor (CAR) T-cell therapy, a form of immunotherapy that has revolutionized the treatment of certain blood cancers, such as B-cell acute lymphoblastic leukemia. CAR T-cell therapy involves extracting a patient’s T-cells—the "soldiers" of the immune system—and genetically engineering them in a laboratory to express specific receptors on their surface. These receptors allow the T-cells to recognize and bind to specific proteins found on cancer cells, leading to their destruction.
However, applying CAR T-cell therapy to solid tumors like Ewing sarcoma has historically proven difficult. Solid tumors present physical barriers and chemical signals that exhaust T-cells before they can eradicate the cancer. To overcome this, Dr. Lee’s team is implementing a novel "armored" CAR T-cell approach. By strategically incorporating Interleukin-18 (IL-18) into the CAR T-cells, the researchers aim to enhance the cells’ longevity and killing capacity.
IL-18 is a potent pro-inflammatory cytokine known for its ability to stimulate the production of interferon-gamma and enhance the activity of natural killer (NK) cells and T-cells. By arming the CAR T-cells with the ability to produce IL-18, Dr. Lee’s method creates a self-sustaining immune response within the tumor site. This not only helps the T-cells survive the hostile environment of the metastatic lesion but also recruits other components of the immune system to join the fight. "Our hope is this treatment can one day lead to better outcomes for kids with this disease by making their immune systems better at fighting the cancer," stated Dr. Lee, who serves as an associate professor in residence in the Division of Hematology/Oncology at UCLA.
The Acceleration Initiative: Bridging the Gap to Clinical Trials
The $900,000 investment in Dr. Lee’s project is part of a broader strategic effort to reduce the "valley of death" in drug development—the gap between laboratory discovery and patient availability. The Acceleration Initiative Award is specifically granted to projects that demonstrate high innovation, address a significant unmet need in pediatric oncology, and possess a high probability of clinical application within an accelerated timeframe.
A distinctive feature of this award is its rigorous timeline. Projects funded under this initiative are anticipated to reach clinical trials within just three years. For children with metastatic Ewing sarcoma, for whom time is the most precious resource, this 36-month window represents a significant shift from traditional research timelines, which can often span a decade or more. By focusing on preclinical efficacy and safety data required for FDA approval of a Phase I trial, Dr. Lee’s work is positioned to move rapidly from the bench to the bedside.
A Collaborative Funding Model and the Power of Legacy
The funding of this project is the result of a multifaceted collaborative model, reflecting the growing trend of "venture philanthropy" in the fight against childhood cancer. The award is supported in part by the Rally Foundation for Childhood Cancer Research and three CureSearch Legacy Funds: Garret and I: The Garret Collins Legacy Fund, The Nick Currey Fund, and The Sam Schneider Legacy.
These legacy funds represent the deeply personal commitment of families who have been directly impacted by Ewing sarcoma. By channeling their grief into a mission for a cure, these families provide the essential capital needed for high-risk, high-reward research. The stories of Garret, Nick, and Sam serve as the driving force behind the urgency of Dr. Lee’s work.
Sam Schneider’s family highlighted the critical issue of late diagnosis in Ewing sarcoma, noting that Sam’s cancer was detected only after it had become metastatic—a common occurrence due to the often-vague symptoms of bone pain in active children. "Sam is deeply missed, but we continue to honor him and his desire to raise awareness of Ewing sarcoma in hopes of enabling increased early detection," his family shared. Similarly, the family of Nick Currey emphasized the need for modern alternatives to the harsh, decades-old treatments currently in use. "If more targeted, less toxic therapies had been available, Nick might be alive today," they stated, underscoring the secondary goal of Dr. Lee’s research: creating treatments that are not only more effective but also less damaging to a child’s developing body.
Broader Implications for Pediatric Oncology
The implications of Dr. Lee’s research extend beyond Ewing sarcoma. If the incorporation of IL-18 into CAR T-cell therapy proves successful in treating ES, the methodology could serve as a blueprint for treating other recalcitrant pediatric solid tumors, such as osteosarcoma or neuroblastoma. The success of this project would validate the "armored CAR T" concept, potentially leading to a new generation of immunotherapies that can withstand the immunosuppressive defenses of various childhood malignancies.
Furthermore, the focus on precision medicine aligns with the global shift toward oncology treatments that spare healthy tissue. Conventional treatments for ES—particularly high-dose radiation and alkylating agents—carry significant risks of long-term side effects, including secondary cancers, heart damage, and infertility. By specifically targeting the unique markers of ES cells, Dr. Lee’s CAR T-cell approach offers a pathway toward a "smarter" therapy that minimizes collateral damage to the patient.
Timeline and Future Milestones
As the project moves forward at the David Geffen School of Medicine at UCLA, the research team will focus on several key milestones over the next three years. The initial phase will involve refining the CAR T-cell construct to ensure maximum specificity for Ewing sarcoma cells, thereby reducing the risk of "off-target" effects where the immune system might attack healthy organs.
Following this, the team will conduct extensive preclinical testing to observe how the IL-18-boosted cells interact with tumor models. If these milestones are met, the project will culminate in an Investigational New Drug (IND) application to the FDA, paved by the support of the Acceleration Initiative.
The collaboration between UCLA, the Rally Foundation, and the legacy funds demonstrates a powerful synergy in the pediatric cancer community. It highlights a shift toward funding research that is not just scientifically curious but clinically directed. For the families of children currently battling metastatic Ewing sarcoma, the progress of Dr. Lee’s team represents more than just scientific data; it represents a tangible move toward a future where a 15% survival rate is a relic of the past. Through the strategic combination of cutting-edge genetic engineering and a commitment to rapid clinical translation, this research stands at the forefront of a new era in pediatric cancer care.
